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Background:Treatment of large bone defects due to trauma, tumor resection, or congen-
ital abnormalities is challenging. Bone tissue engineering using mesenchymal stem cells
(MSCs) represents a promising treatment option. However, the quantity and quality of
engineered bone tissue are not sufficient to fill large bone defects. The aim of this study
was to determine if the addition of enamel matrix derivative (EMD) improves in vitro chon-
drogenic priming of MSCs to ultimately improve in vivo MSC mediated endochondral bone
formation.
Methods: MSCs were chondrogenically differentiated in 2.0×105 cell pellets in medium
supplemented with TGFβ3 in the absence or presence of 1, 10, or 100µg/mL EMD. Sam-
ples were analyzed for gene expression of RUNX2, Col II, Col X, and Sox9. Protein and
glycoaminoglycan (GAG) production were also investigated via DMB assays, histology,
and immunohistochemistry. Osteogenic and adipogenic differentiation capacity were also
assessed.
Results:The addition of EMD did not negatively affect chondrogenic differentiation of adult
human MSCs. EMD did not appear to alter GAG production or expression of chondrogenic
genes. Osteogenic and adipogenic differentiation were also unaffected though a trend
toward decreased adipogenic gene expression was observed.
Conclusion: EMD does not affect chondrogenic differentiation of adult human MSCs. As
such the use of EMD in combination with chondrogenically primed MSCs for periodontal
bone tissue repair is unlikely to have negative effects on MSC differentiation.
Keywords: enamel matrix derivative, chondrogenesis, mesenchymal stem cells, endochondral ossification,
periodontal diseases, differentiation, scaffolds
INTRODUCTION
Trauma, tumor resection, or congenital abnormalities can result in
large bone defects in the craniomaxillofacial region as well as else-
where in the body. Treatment options of such defects include the
use of autologous or allogenic bone or other substitutes (Arring-
ton et al., 1996; Froum et al., 2001). Autologous bone is preferred
clinically; however, harvesting of material can result in secondary
site morbidity and an increased risk of infection (Arrington et al.,
1996). In addition, tissue availability is limited, increasing the
demand for an alternative graft substitute (Meijer et al., 2008).
Tissue engineering represents a promising alternative treatment
option for such defects. Mesenchymal stem cells (MSCs), avail-
able from tissues including bone marrow and adipose tissue, are
multipotent cells that can be differentiated the osteogenic and
chondrogenic lineages (Pittenger et al., 1999) making them an
attractive cell source for bone tissue engineered constructs.
Multiple approaches have been taken to improve osteogenic dif-
ferentiation of MSCs, mimicking the process of intramembranous
ossification, including manipulating growth factors, scaffolds, and
environmental parameters (e.g., oxygen and pressure) (Salgado
et al., 2004). Unfortunately, because these bone tissues lack vascu-
lature, necrosis, improper nutrient delivery, and inadequate waste
removal occur, ultimately resulting in graft failure.
Bone tissue constructs modeled after the process of endochon-
dral ossification (EO) may result in more promising outcomes as
the tissue would be better suited to survive the initial avascular
implantation site. During EO, cartilage is formed by chondro-
genic differentiation of MSCs in vitro. Since chondrocytes reside
in an avascular environment, they can survive the initial hypoxic
insult following implantation (Coyle et al., 2009). As the chondro-
cytes mature, become hypertrophic, and apoptose, blood vessels
invade and the cartilage rich matrix is mineralized and serves as a
template for future bone development. Several groups have pro-
duced promising results on the ability of MSCs to guide bone
formation along the process of EO in vivo (Huang et al., 2006;
Farrell et al., 2009, 2011; Gawlitta et al., 2010; Janicki et al., 2010;
Scotti et al., 2010; Thompson et al., 2014). van der Stok et al.
(2014) demonstrated proof of principle in repairing a long bone
defect using this approach. However, despite the promise of this
approach, the resulting bone is not sufficient to fill large clinically
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relevant defects, indicating a need to improve current techniques
to optimize bone return. Many researchers have investigated com-
bining MSC with clinically relevant compounds to improve in vivo
bone formation.
Enamel matrix derivative (EMD) is an extracellular matrix
derivative obtained from porcine tooth buds. It contains amelo-
genin and proteins that belong to the amelogenin family (>90%)
(Grandin et al., 2012). It is sold commercially as Emdogain in a
single dose syringe dissolved in propylene glycol alginate. Emdo-
gain is used clinically to stimulate the regeneration of periodontal
tissues. Combining EMD with surgical periodontal therapy (sur-
gical therapy of the tissue surrounding or encasing teeth) of
deep intrabony defects leads to improvement in clinical para-
meters compared to surgical therapy alone (Froum et al., 2001).
Studies have shown that EMD stimulates the proliferation and
osteogenic differentiation of MSCs (Narukawa et al., 2007a; Jue
et al., 2010; Song et al., 2010; Grandin et al., 2012). However,
many groups used only specific proteins that are included in
EMD or based their results on cells obtained from animals or
cell-lines. The research group of Narukawa found a stimula-
tory effect of Emdogain on the expression of chondrogenesis-
related transcription factors in chondrogenically primed MSCs.
Utilizing a chondrogenic cell line, the group also observed an
increase in the amount of glycosaminoglycans (GAGs) formed
in the extracellular matrix (Narukawa et al., 2007a,b). In an
additional study, EMD was shown to increase the proliferation
of early chondrocytes derived from rats and inhibited matura-
tion. In more mature chondrocytes, EMD enhanced prolifera-
tion and no longer inhibited differentiation (Dean et al., 2002).
Due to its clinical relevance and previous evidence indicating
an improvement in chondrogenesis, at least on gene expression
in a chondrogenic cell line, EMD was hypothesized to improve
in vitro chondrogenic priming of human MSCs. These chon-
drogenically primed human MSCs could be implanted in order
become hypertrophic and mineralized leading toward bone for-
mation via EO in vivo. Assuming this to be the case, it was
hypothesized that these primed cells would lead to improved bone
formation in vivo. The aim of this research was to determine if
EMD enhanced chondrogenesis in human MSCs and to determine
if EMD improves the quantity and quality of the chondrogenic
matrix production. In order to compare with previous research,
we also assessed the osteogenic capacity of MSCs in the presence of
varying doses of MSCs as well as their adipogenic differentiation
capability.
MATERIALS AND METHODS
EMD
Enamel matrix derivative was supplied as a freeze dried prepa-
ration by Straumann Company. It was reconstituted in 50 mM
acetic acid to 10 mg/mL and further diluted to the working
concentrations below in the appropriate culture medium.
MSC ISOLATION
Mesenchymal stem cells were isolated from three human bone
marrow samples aspirated from the greater trochanter major from
patients undergoing total hip arthroplasty, after informed consent
(METC 2004-142). There were two females (aged 20 and 60) and
one male (aged 54). Cells from each donor showed similar growth
and differentiation characteristics. Cells were maintained in
expansion medium,α-mem (Gibco) containing 10% FCS (Lonza),
supplemented with 1 ng/mL FGF2 and 25µg/mL Ascorbic acid at
37°C and 5% CO2 as described previously (Leijs et al., 2012).
ADIPOGENESIS
Mesenchymal stem cells were cultured in 12-well plates at a den-
sity of 7.98× 105 cells/well. Cells were cultured for 14 days at
37°C and 5% CO2 in adipogenic induction medium, DMEM
containing 10% FCS, supplemented with 1µM dexametha-
sone, 0.2 mM indo-methacin, 0.01 mg/mL insulin, and 0.5 mM
3-isobutyl-l-methyl-xanthine (Sigma). EMD treated samples were
cultured in 1, 10, or 100µg/mL EMD or vehicle alone (0.5 mM
acetic acid). Medium was replaced twice a week.
OSTEOGENESIS
Mesenchymal stem cells were cultured in 12-well plates at a density
of 1.14× 104 cells per well. Cells were cultured for 15–19 days at
37°C and 5% CO2 in osteogenic induction medium, high-glucose
DMEM (Invitrogen) with addition of 10% FCS, 50µg/mL gen-
tamycin (Invitrogen), 1.5µg/mL fungizone (Invitrogen), 10 mM
glycerol 2-phosphate (Sigma), 0.1µM dexamethasone (Sigma),
and 0.1 mM ascorbic acid (Sigma). EMD treated samples were cul-
tured in 1, 10, or 100µg/mL EMD or vehicle. Medium was replaced
twice a week. Samples were harvested at the latest point prior to
detachment of the cells from the surface of the tissue culture plas-
tic, as occurs during osteogenic differentiation in monolayer. This
varied from 15–19 days between donors.
CHONDROGENESIS
Mesenchymal stem cells were cultured for 21 or 35 days in pel-
lets of 2.0× 105 cells in chondrogenic medium, high-glucose
DMEM supplemented with 50µg/mL gentamycin (Invitrogen),
1.5µg/mL fungizone (Invitrogen), 1 mM sodium pyruvate (Invit-
rogen), 40µg/mL proline (Sigma), 1:100v/v insulin-transferrin-
selenium (ITS; BD Biosciences), 10 ng/mL transforming growth
factor β1 (R&D Systems), 25µg/mL ascorbic acid (Sigma), and
100 nM dexamethasone (Sigma). EMD treated samples were cul-
tured in 1, 10, or 100µg/mL EMD or vehicle alone. Medium was
replaced twice a week.
OIL RED O STAINING
Lipid droplets were stained by Oil Red O. Cells in monolayer were
washed in 0.9% NaCl and fixed for 1 h in 4% paraformaldehyde.
Cells were stained with Oil Red O (0.3% w/v in distilled water;
Sigma) for 10–15 min and washed with distilled water. Cells were
mounted with Vectamount.
von KOSSA STAINING
Cells in monolayer were washed in 0.9% NaCl, fixed with 4%
formaldehyde for 1 h and stained with von Kossa staining. Cells
were incubated in 5% silver nitrate and placed on a light box for
15 min. Excess silver nitrate was washed using distilled water and
cells were placed on a light box for another 10 min. Cells were
washed in distilled water and counterstained with thionine for
5 min. Cells were dehydrated in 70% (10 s), 96% (30 s), and 100%
ethanol (2 min) and mounted with Vectamount.
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FIGURE 1 | Measurement of gene expression levels for osteogenic genes. Gene expression was measured in MSCs cultured in osteogenic medium for
15–19 days. Data represent fold changes of target genes relative to the housekeeping gene GAPDH. Values represent the mean±SD for samples from
three donors.
SCAFFOLD SEEDING
Collagen-glycosaminoglycan (Collagen-GAG) scaffolds were cut
in 8 mm squares, placed in 6-well plates coated with 2% agarose
(LE- analytical grade, Promega). Scaffolds were seeded with
5× 105 cells in 150µL culture medium on one side, incubated for
30 min then overturned and seeded again with the same cell num-
ber and volume. After another 30 min, the well was filled with 3 mL
of culture medium. Constructs were cultured in chondrogenic
medium with the addition or absence of 10 ng/mL transforming
growth factor-β 1 (TGF-β1) and/or 100µg/mL EMD. Samples
were cultured at 37°C and 5% CO2.
GENE EXPRESSION ANALYSIS
RNA was isolated from chondrogenic pellets by homogenizing
samples with a Eppendorf-potter in 350µL RNAbee (Freund
Can Company). Adipogenic and osteogenic primed MSCs cul-
tured in monolayers, 2-wells were combined in 300µL RNAbee.
RNA isolation, cDNA synthesis, and measurement of gene expres-
sion levels on 8–15 ng cDNA were performed as described before
(Verseijden et al., 2009; Leijs et al., 2012). Primers and probes
used for alkaline phosphatase (ALPL), Gamma-carboxyglutamic
acid-containing protein (BGLAP), Integrin-binding sialoprotein
(IBSP), Collagen type I (COLI), Peroxisome proliferator-activated
receptor γ (PPARγ), Fatty acid-binding protein 4 (FABP4),
Runt-related transcription factor 2 (RUNX2), Collagen type II
(COL II), Collagen type X (COL X), Sex determining region
Y-box 9 (SOX 9), and Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) are represented in Table S1 in Supplementary
Material.
GLYCOSAMINOGLYCAN QUANTIFICATION
Pellets and scaffolds were digested in 150µL papaine digestion
solution in combination with 150µL sodium citrate buffer. GAGs
were measured and adjusted to the amount of DNA present in each
pellet or scaffold as described before using heparin (Leo Pharma-
ceutical Products BV), RNAse (Ribonuclease type III-A; Sigma),
and ethidium bromide (GibcoBR1) (Clockaerts et al., 2011).
HISTOLOGICAL PREPARATION
Pellets and scaffolds were fixed in 4% paraformaldehyde for 1 h,
embedded in liquid paraffin wax, and cut into 5µm sections
using a microtome (Leica RM2135). Sections were placed onto
SuperStar® microscope slides and de-waxed by soaking sequen-
tially in xylene and 100, 96, and 70% ethanol (5 min each).
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FIGURE 2 | Evidence of osteogenic differentiation of MSCs exposed to
osteogenic factors for 19 days. Images represent von Kossa staining for
MSCs of one donor cultured in the non-differentiation medium α-MEM as a
negative control (A) MSCs cultured in osteogenic differentiation only
(B), MSCs cultured in osteogenic differentiation medium in presence of the
vehicle (C), and MSCs cultured in osteogenic differentiation medium in
presence of 1, 10, or 100µg/mL EMD (D–F) (100× magnification). Arrows
indicate calcium phosphate-containing nodules.
FIGURE 3 | Measurement of gene expression levels for PPARγ and
FABP4. Gene expression was measured in MSCs cultured in adipogenic
differentiation medium for 14 days with addition of vehicle or different doses
of EMD (1, 10, or 100µg/mL). Data represent fold changes of target genes
relative to the housekeeping gene GAPDH. Values represent the mean±SD
for samples from three donors.
GLYCOSAMINOGLYCAN AND H&E STAINING
Glycoaminoglycan formation was determined by 0.1% safranin O
staining and cell morphology was determined utilizing H&E stain-
ing. Stainings were performed as described previously (Narcisi
et al., 2012; de Vries-van Melle et al., 2013).
IMMUNOHISTOCHEMICAL STAINING FOR COLLAGEN TYPE II
Antigen retrieval was performed using 0.1% pronase and 1%
hyaluronidase. Sections were incubated with 1:100 mouse mono-
clonal antibody against collagen type II and stained by an ALPL
substrate as described before (Narcisi et al., 2012).
STATISTICS
Data are presented as mean values±SD. Statistical analysis was car-
ried out using repeated measures ANOVA test followed by Tukey
post hoc correction using a statistical software package (Prism
5.00, Graphpad Software). Results were considered statistically
significant at p< 0.05.
RESULTS
EMD DOES NOT AFFECT THE OSTEOGENIC DIFFERENTIATION CAPACITY
OF HUMANMSCs
Osteogenic genes ALPL, BGLAP, IBSP, and COL I were analyzed
after 15–19 days by real-time PCR. No differences were observed
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FIGURE 4 | Oil Red O staining illustrates adipogenic differentiation
of MSCs exposed to adipogenic factors for 14 days. Images
represent MSCs cultured in the non-differentiation medium α-MEM
(A), MSCs cultures in adipogenic differentiation medium only
(B), MSCs cultured in adipogenic differentiation medium in addition of
vehicle only (0.5 mM acetic acid) (C), and MSCs cultured in adipogenic
differentiation medium in addition of 1, 10, or 100µg/mL EMD
(D–F) (100× magnification).
FIGURE 5 | Gene expression levels of chondrogenic genes following
differentiation. (A) Gene expression was measured in MSCs cultured in
chondrogenic differentiation medium treated with vehicle only or different
doses of EMD (1, 10, or 100µg/mL) for 35 days. Data represent fold changes
of target genes relative to the housekeeping gene GAPDH. Values represent
the mean±SD for samples from three donors. (B) Quantification of GAGs in
MSCs cultured with chondrogenic factors. Data represent amount of GAGs
normalized to DNA content in each pellet.
between osteogenic control, vehicle, and the different doses of
EMD (p-values respectively 0.1600, 0.2578, 0.6016, and 0.5673;
Figure 1). Despite inter-donor variability, no differences were
observed in the amount of calcium phosphate-nodules formed
at the macroscopic level (Figure 2). This suggests that EMD had
no effect on the osteogenic differentiation of MSCs.
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FIGURE 6 | Histological analysis of chondrogenic differentiation of MSCs
exposed to chondrogenic factors for 35 days. Images represent MSCs
cultured in chondrogenic differentiation medium only (A,F), MSCs cultured in
chondrogenic differentiation medium in addition of vehicle only (B,G), and
MSCs cultured in chondrogenic differentiation medium in addition of 1µg/mL
(C,H), 10µg/mL (D,I), or 100µg/mL EMD (E,J). GAGs were stained by
Safranin O (A–E), COL II immunohistochemistry was performed for
images (F–J).
EMD HAS NO EFFECT ON THE ADIPOGENIC DIFFERENTIATION OF
HUMANMSCs
Adipogenic genes, FABP4 and PPARγ, were investigated for three
donors by real-time PCR after 14 days to determine the role of
EMD on adipogenesis. Cells cultured in the high dose EMD
(100µg/mL) showed a trend toward inhibition of gene expression
compared to vehicle and adipogenic control. However, given the
large inter-donor variability, this difference was not statistically sig-
nificant for FABP4 (p= 0.4835) or PPARγ (p= 0.1063; Figure 3).
The effects of vehicle and EMD on adipogenic differentiation were
also assessed by Oil Red O staining of fat-containing droplets.
No cells cultured in the expansion medium (used as a negative
control) showed evidence of fat-containing droplets (Figure 4A).
When MSCs were cultured in all other treatment conditions, cells
positively stained in all conditions (Figures 4B–F). Staining was
slightly reduced in the high dose EMD (100µg/mL) compared to
adipogenic control or vehicle across all donors and wells. This sug-
gests, together with the results for FABP4 and PPARγ, a potentially
inhibitory effect of EMD on adipogenic differentiation of MSCs at
the highest dose. However, this effect was minimal as determined
by staining.
EMD DOES NOT AFFECT THE CHONDROGENIC DIFFERENTIATION
CAPACITY OF HUMANMSCs
Chondrogenically primed cell pellets were analyzed by real-time
PCR after 21 days for three donors. Four different chondrogenic
genes were analyzed; COL II, COL X, SOX 9, and RUNX2
(Figure 5). After treatment with vehicle only or EMD, no statistical
significant differences in COL II (p= 0.0538),COL X (p= 0.2457),
SOX 9 (p= 0.7458), or RUNX2 (p= 0.5863) mRNA levels were
observed between groups.
GAG-production measured in control was approximately 40µg
GAG per microgram DNA. There was no effect of EMD at any
concentration on the quantity of GAG production (p= 0.8989;
Figure 5B). Following 35 days of culture in chondrogenic medium,
or in the presence of vehicle, or EMD, chondrogenic pellets
were stained with safranin O (Figures 6A–E). Immunohistochem-
ical staining for COL II was also performed on these pellets
(Figures 6F–J). All pellets demonstrated high quantities of GAGs
stained by safranin O and collagen type II. However, no differences
in staining were observed between pellets in the chondrogenic
control conditions or in the presence of different doses of EMD
(1, 10, or 100µg/mL).
MSCs IN 3D CULTURE
In order to assess the effects of EMD on the cell distribu-
tion and chondrogenic differentiation in a 3D environment, two
collagen-GAG scaffolds were seeded with human MSCs and cul-
tured in the presence or absence of TGFβ1 (10 ng/mL) and/or
EMD (100µg/mL). Hematoxylin and eosin staining demonstrated
similar cellular distribution in both conditions (Figures 7A–D).
Thionine staining illustrated the presence of GAGs in both
conditions (Figures 7E–H). Upon quantification of the amount
of GAG production in two scaffolds per condition, less GAG/DNA
was produced in the TGFβ1+ EMD condition (Figure 8). As this
was only performed with cells from one donor, it was not possible
to statistically analyze these results.
DISCUSSION
Treatment of large bone defects is challenging. Current treat-
ment options such as autologous bone or bone substitutes are
often accompanied by limitations and serious complications,
highlighting the necessity for an alternative treatment option to
be developed (Arrington et al., 1996; Meijer et al., 2008; Vahabi
et al., 2012; Wiggins et al., 2012). Reports on the ability of EMD
to improve MSC osteogenesis are mixed (Narukawa et al., 2007b;
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FIGURE 7 | (A–D) Distribution of MSCs through the collagen-GAG scaffolds cultured under the four different conditions (H&E staining). (E–H) Staining for GAGs
produced by MSCs seeded on collagen-GAG scaffolds cultured whether or not in presence of TGF-β and/or EMD (thionine staining).
Gawlitta et al., 2010; Jue et al., 2010; Qu et al., 2010; Grandin
et al., 2012) while little is known about the effects of EMD on
chondrogenesis of human MSCs. Bone formation utilizing EO,
in which MSCs are chondrogenically differentiated in vitro, and
implanted, forming bone in vivo, represents a promising new
avenue of research in the field of bone tissue engineering (Gawlitta
et al., 2010). We hypothesized that, given the reported abilities of
EMD to improve cell proliferation, migration, and differentiation
(particularly osteogenically) (Narukawa et al., 2007a; Jue et al.,
2010; Qu et al., 2010; Song et al., 2010), EMD might also improve
the chondrogenic priming of human MSCs. In this study, we
focused on chondrogenic differentiation of adult human MSCs
as a first step to tissue engineering bone via the process of EO.
In order to put the work in the context of prior research, we also
assessed osteogenic and adipogenic differentiation of these cells in
the presence of EMD.
No differences were observed in GAG production nor in COL II
expression in any of the conditions. While the group of Narukawa
found an upregulation of COL II, COL X, and SOX 9, as well as
increased GAG production following chondrogenic treatment of
the ATDC5 hypertrophic cell line in the presence of Emdogain
(Narukawa et al., 2007a), we observed no effects on chrondro-
genic differentiation in primary human MSCs. Given the natural
tendency of these teratoma derived ATDC5 cells to progress along
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FIGURE 8 | Quantification of GAGs in MSCs seeded on scaffolds
cultured with chondrogenic factors for 21 days (two samples from one
donor for each condition).
the chondrogenic lineage toward hypertrophy, it is hard to directly
compare the two cell types. The effect of EMD on cell migration
and chondrogenesis in a 3D environment, a collagen-GAG scaf-
fold, was also analyzed in this study. This was only performed
using cells from a single donor on two scaffolds per condition. On
histology, no differences were observed between chondrogenically
treated groups. However, while chondrogenisis did occur, there
was a trend toward decreased GAG production in the EMD treated
samples. This experiment would require repetition with MSCs
from several donors to confirm if this is the case.
We observed no effect of EMD at any dose on the ability of
cells extracellular matrix production or on the gene level when
stimulated osteogenically. This is in agreement with the work of
some other groups (van den Dolder et al., 2006; Mrozik et al.,
2012). However, other groups also stated EMD, or components
of it, stimulated the differentiation of MSCs toward osteocytes
(Keila et al., 2004; Itoh et al., 2006; Narukawa et al., 2007b; Amin
et al., 2012; Ramis et al., 2012). These groups utilized both cell-
lines and rat derived MSCs, as well as only selective proteins found
in EMD, which may explain the differences observed. Consid-
ering published work and our results, we have no evidence to
support the idea that EMD would negatively influence osteogenic
differentiation of human MSCs. The in vivo effects of EMD on
ossification remain unclear. Some groups reported enhanced bone
induction in vivo in both animals and humans (Hammarstrom
et al., 1997; Boyan et al., 2000; Jaiswal and Deo, 2013) while others
showed no effect of EMD on the formation of mineralized bone
(Schneider et al., 2011). Yagi showed that EMD inhibits RANKL
expression, resulting in inhibited osteoclast formation, the cells
that are responsible for bone resorption (Yagi et al., 2009). The
variability in these results could be caused by factors such as bio-
logical characteristics of the defect and patient variability (Venezia
et al., 2004). However, these results are based on bone forma-
tion by surrounding cells instead of implanted chondrogenically
primed cells. It is difficult to extrapolate the results observed in this
study to the in vivo/clinical situation. We observed a mild trend
toward inhibition of adipogenic differentiation at the highest dose
of EMD on human MSCs. No tests have been performed to deter-
mine the effects of EMD on adipogenic differentiation of MSCs
previously. The decreasing trend toward adipogenic differentia-
tion of MSCs, in this proposed application, could be considered
a positive outcome suggesting undesirable fat tissue formation is
unlikely.
Enamel matrix derivative does not appear to effect the mul-
tilineage differentiation of human MSCs. There may be a slight
inhibitory effect of EMD, at the highest dose, on adipogenesis.
However, this was not proven to be statistically significant. While
this work suggests that EMD would not increase the chondro-
genic potential of MSCs, which could be utilized in a bone tissue
construct via EO for the treatment of large bone defects, there is
also no evidence that bone formation would be inhibited if EMD
was used in combination with MSCs for the repair of minor bone
defects for periodontal tissue repair.
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